Clinical Trial Update: Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the efficacy of orally disintegrating selegiline in Parkinson's disease patients experiencing adverse effects with dopamine agonists; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Selegiline (orally disintegrating) (selegiline)

Snippet

Sponsor: Parkinson's Disease and Movement Disorder Center of Boca Raton | Conditions: Parkinson's Disease | Phase 4 | Status: COMPLETED | Results posted: 2014-10-31